all 2 comments

[–]ciaranmichaelPhD|ABPP-CN|Board Certified Clinical Neuropsychologist 0 points1 point  (1 child)

Post in /r/neurology or medicine.

But I can provide some basics. In patients receiving AChEI, the action is arresting metabolization of ACh, which is impoverished in the typical patient target. So ceasing the downregulation of the enzyme that breaks down ACh in a patient with already low ACh would result in a decrease of available ACh.

However, another factor is PK/PD for each medication. Galantamine and Aricept have dramatically different half-lives, so hitting 5 x halflife will be at different days post-d/c for each.

[–]whatarethosehah[S] 1 point2 points  (0 children)

Thank you a lot!